Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome

Duvic, Madeleine

doi:10.1182/asheducation-2015.1.529

Cited by 18 publications

(10 citation statements)

References 213 publications

(249 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with limited‐stage disease are best managed with skin‐directed therapies, whose goal is to induce durable remissions, while advanced‐stage patients tend to benefit more from multidisciplinary approaches that combine local and systemic therapies. In both settings, multiagent chemotherapy is generally postponed until possible, in order to avoid excessive toxicity and immunosuppression …”

Section: Discussionmentioning

confidence: 99%

“…In both settings, multiagent chemotherapy is generally postponed until possible, in order to avoid excessive toxicity and immunosuppression. 1,2,9 This SS patient represent a symbolic "highlander" because in Patient's medical history. CR: complete response; GPR: good partial response; NR: no response; PR: partial response; PUVA: psoralen and ultraviolet A; SD: stable disease (7 y) at the beginning of the disease (gemcitabine was the second line of treatment) and to mogamulizumab (15 mo) in a situation of heavily pretreated patient and disease (it was the tenth line of treatment).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies

Nanni

Morigi

Casadei

et al. 2019

Hematological Oncology

View full text Add to dashboard Cite

Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16‐year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Patient refused to undergo allogeneic stem cell transplantation. After eleven lines of therapeutic approaches, the patient is in very good partial response and free of therapy at the latest available follow‐up.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies

Nanni

Morigi

Casadei

et al. 2019

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Efficacy and safety of adenosine analogues to treat severe and refractory psoriasis need to be assessed in a larger series of patients, since pentostatin, like many other agents including those used for psoriasis treatment, is known for different toxicities and side effects [ 18 , 19 ], including hematologic and renal insufficiency, opportunistic infections, nausea, and conjunctivitis. Pentostatin has also been associated with angina and myocardial infarction, heart failure, and acute arrhythmias in patients with predisposing conditions and comorbidities [ 18 – 20 ]. These molecules might also be of interest for the treatment of psoriatic arthritis.…”

Section: Discussionmentioning

confidence: 99%

“…These molecules might also be of interest for the treatment of psoriatic arthritis. Lower doses of pentostatin or cladribine than those prescribed in malignant disorders and use of oral dosage forms of these molecules might been investigated to help decrease the risk of side effects, in particular infections [ 18 – 21 ].…”

Section: Discussionmentioning

confidence: 99%

Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report

Alsuliman

Lassoued

Belghoul

et al. 2017

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

IntroductionPentostatin (2′-deoxycoformycin) and cladribine (2-chlorodeoxyadenosine) are adenosine analogues widely used to treat lymphoid malignancies, mainly hairy cell leukemia (HCL). Oral or parenteral adenosine analogues have been also used as immunomodulatory agents in multiple sclerosis and in acute graft-versus-host disease.Case ReportHere, we report the case of a 43-year-old patient with a history of extensive psoriasis who later developed HCL.ResultsThe patient had achieved complete remission of both psoriasis and HCL after receiving intravenous infusions of pentostatin. It is worth noting that cladribine has already been reported to treat plaque psoriasis lesions in two patients with HCL and in a third patient with gastric marginal zone B cell lymphoma [1].ConclusionWe believe that adenosine analogues constitute a promising therapeutic option for moderate to severe psoriasis, especially for severe and refractory psoriasis, as well as for patients with adjacent lymphoid malignancies.

show abstract

“…cutaneous T-cell lymphoma (CTCL) [4][5][6][7][8][9]. Mogamulizumab (also named as KW-0761, poteligeo) is a humanized, IgG1 kappa monoclonal antibody that is directed against CCR4 [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy Profile of Mogamulizumab (Poteligeo) in the Treatment of Cancers: An Update Evidence From 14 Studies

Zhang

Sun

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: CC chemokine receptor 4 (CCR4) is the receptor for CCL22 and CCL17, which is expressed on the surface of tumor cells from patients with adult T-cell leukemia/lymphoma (ATL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Mogamulizumab is a humanized, IgG1 kappa monoclonal antibody that is directed against CCR4. By reducing the number of CCR4 positive Treg cells, the mogamulizumab can boost antitumor immunity and achieve anti-tumor effects.Methods: We examined the PubMed and ClinicalTrials.gov without any language restrictions until 1 February 2020. Considering variability in different studies, the overall survival (OS), progression‐free survival (PFS), objective responses rate (ORR) and Hazard Ratio (HR) were selected to evaluate the efficacy. Besides, adverse events (AEs) were calculated to assess the safety.Results: When patients were treated with mogamulizumab monotherapy, the most common all-grade AEs were lymphopenia, infusion reaction, fever, rash and chills while lymphopenia, neutropenia and rash were the top 3 grade ≥3 AEs. In combination therapies, the top 3 all-grade AEs were neutropenia, anaemia, and lymphopenia, and lymphopenia is the most common grade ≥3 AE. Besides, the overall ORR is 0.430 (95% CI: 0.393-0.469) and the pooled mean PFS is 1.060 months (95% CI: 1.043-1.077) in mogamulizumab monotherapy. In combination therapies, the overall ORR is 0.203 (95% CI: 0.022-0.746) while the overall PFS and OS were 2.093 months (95% CI: 1.602-2.584) and 6.591 months (95% CI: 6.014-7.167), respectively.Conclusions: On the basis of present evidence, we believed that mogamulizumab had clinically meaningful antitumor activity with acceptable toxicity which had a considerable potential in treating patients with cancers.

show abstract

Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome

Cited by 18 publications

References 213 publications

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies

Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report

Safety and Efficacy Profile of Mogamulizumab (Poteligeo) in the Treatment of Cancers: An Update Evidence From 14 Studies

Contact Info

Product

Resources

About